Cheaper Drugs for the Uninsured
Express Scripts will offer a lower rate for some drugs used by people in high-deductible health plans or by people who have no insurance. The program is free, and consumers will get discounts on drugs at pharmacies around the country, reported The New York Times. The discounts average one-third off the list price. Some of the drugs that will be part of the program are Crestor, which lowers cholesterol, and some brands of insulin. Overall, there are 40 products on the list.
Life Expectancy Disparities in the US
Depending on the county, life expectancy in the United States can look very different. According to The Washington Post, life expectancy is greatest in the middle of Colorado, where people in some counties can expect to live more than 85 years, and lowest in nearby South Dakota, where some counties reported a life expectancy of 67 years. While income and exercise impact longevity, so did access to healthcare, and the study implies that the country needs to reconsider how it delivers care.
Duchenne Drug Gets $35K Price Tag
Before Marathon sold its drug to treat Duchenne muscular dystrophy, it had set a $89,000 list price, and the new owner promised a lower price tag. PTC Therapeutics has announced the annual price for Emflaza will be $35,000. Despite the lower price, the drug has been available overseas for as low as $1000 a year, and RBC Capital Markets had estimated the price from PTC would actually be $10,000 lower. In addition, since the treatment is based on patient weight, the cost will be more for patients who weigh more.
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen